Price$26.19-0.95 (-3.50%)
01:30 PM07:45 PM
News · 26 weeks103+33%
2025-12-142026-06-07
Mix6790d
- Insider30(45%)
- Other20(30%)
- SEC Filings8(12%)
- Analyst5(7%)
- Leadership2(3%)
- Earnings2(3%)
Latest news
25 items- PRHims & Hers Names Dr. Anant Vinjamoori as Chief Medical Officer of HimsAn expert in longevity medicine and preventive healthcare, Vinjamoori joins Hims & Hers to help more men feel great at every stage of life Hims & Hers Health, Inc. (NYSE:HIMS), the leading health and wellness platform, today announced Dr. Anant Vinjamoori is joining as the Chief Medical Officer of the Hims brand. As the company reimagines how everyone can access proactive, comprehensive care that helps them feel great, Dr. Vinjamoori will provide the clinical guidance that shapes the next phase of the Hims brand across sexual health, hormone health, dermatology, weight loss, and mental health, as well as emerging categories like longevity medicine and peptide therapy. He joins a team of m
- SECHims & Hers Health Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Other Events, Financial Statements and Exhibits8-K - Hims & Hers Health, Inc. (0001773751) (Filer)
- PRHims & Hers Completes Acquisition of Eucalyptus, Accelerating Its Push to Transform Healthcare for CanadiansBuilding on its Canadian launch and the historic introduction of generic semaglutide, Hims & Hers brings the full power of the world's largest consumer health platform — and Juniper's proven track record — to more Canadians than ever Hims & Hers Health, Inc. today announced the completion of its acquisition of Eucalyptus, the parent company of Juniper, marking the latest in a series of significant company investments in Canada. Since launching in 2025, Hims & Hers has already changed the game in Canada, becoming the first platform to bring generic semaglutide to eligible Canadians. By combining Juniper's proven platform with the technology, data, and clinical infrastructure that has advan
- PRHims & Hers Completes Acquisition of Eucalyptus, Expanding Access to Comprehensive, Clinically-Backed Weight Management Care in GermanyClosing brings world-class technology and clinical infrastructure to a market where Juniper has helped patients achieve clinically meaningful weight loss Hims & Hers Health, Inc. has completed its acquisition of Eucalyptus, the parent company of Juniper, advancing its position as the world's largest consumer health platform. In Germany, the closing strengthens Juniper's comprehensive, clinically rigorous, weight management offering with the technology, data, and infrastructure of Hims & Hers behind it. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260602926942/en/Closing brings world-class technology and clinical infrastructu
- PRHims & Hers Completes Acquisition of Eucalyptus, Advancing its Position as the World's Largest Consumer Health PlatformThe acquisition extends the company's leadership position across Australia, Canada, Germany, Japan, and the United Kingdom, with the scale to redefine healthcare for hundreds of millions of people Hims & Hers Health, Inc. (NYSE:HIMS) has completed its acquisition of Eucalyptus, advancing its position as the world's largest consumer health platform. Building on the earlier acquisitions of ZAVA and Livewell, Hims & Hers now has a leading presence across the US, UK, Australian, and Canadian markets, with a growing presence in France, Germany, Ireland, Spain, and Japan. Continuing to expand internationally will enable Hims & Hers to lead the next era of digital health, delivering personal, af
- PRHims & Hers Completes Acquisition of Eucalyptus, Parent Company of Juniper, Officially Entering Japanese MarketClosing brings the scale, technology and clinical infrastructure of Hims & Hers to Japan Hims & Hers Health, Inc. has completed its acquisition of Eucalyptus, the parent company of Juniper, marking a significant milestone in the company's global growth and its formal entry into Japan. This milestone puts the full weight of Hims & Hers' technology, data, and clinical infrastructure behind a platform that supports weight management care for people in Japan, a market the company approaches with deep respect for its distinct healthcare values and the trust people place in those who serve them. This press release features multimedia. View the full release here: https://www.businesswire.com/ne
- PRHims & Hers Completes Acquisition of Eucalyptus, Advancing Position as the World's Largest Consumer Health PlatformEntering Australia for the first time, Hims & Hers will combine scale, technology, and clinical expertise to make personalised, whole-body care more accessible to every Australian Hims & Hers Health, Inc. has completed its acquisition of Eucalyptus – the parent company of Juniper, Pilot, Kin, and Software – advancing its position as the world's largest consumer health platform and marking its official entry into Australia. This milestone puts the full weight of Hims & Hers' technology, data, and clinical infrastructure behind a platform that has already transformed how over half a million Australians have accessed care. This press release features multimedia. View the full release here:
- PRHims & Hers Expands Benefits for Active Subscribers With Eight New Health and Wellness PartnersFrom connected fitness and cycle tracking to meal delivery and glucose monitoring, Hims & Hers subscribers now have ten ways to support their whole-body health Hims & Hers Health, Inc. (NYSE:HIMS), the leading health and wellness platform, today announced the expansion of Hims & Hers Benefits, adding eight new partners to the Hims & Hers exclusive program. Joining founding partners Prenuvo and Eight Sleep are Natural Cycles, MyFitnessPal, Ladder, PVOLVE Studios, HelloFresh, Factor, Flo Health, Dexcom, and iFIT - a carefully curated lineup spanning nutrition, fitness, women's health, metabolic monitoring, and connected wellness. This press release features multimedia. View the full releas
- INSIDERDirector Wells David B bought $1,172,974 worth of shares (48,400 units at $24.23), increasing direct ownership by 27% to 224,417 units (SEC Form 4)4 - Hims & Hers Health, Inc. (0001773751) (Issuer)
- INSIDERSEC Form 4 filed by Chief Medical Officer Carroll Patrick Harrison4 - Hims & Hers Health, Inc. (0001773751) (Issuer)
- INSIDERSEC Form 4 filed by Director Wells David B4 - Hims & Hers Health, Inc. (0001773751) (Issuer)
- INSIDERSEC Form 4 filed by Director Payne Christopher D4 - Hims & Hers Health, Inc. (0001773751) (Issuer)
- SECHims & Hers Health Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities8-K - Hims & Hers Health, Inc. (0001773751) (Filer)
- PRHims & Hers Expands GLP-1 Offering in Canada with Generic SemaglutideBy introducing access to generic semaglutide in Canada, the company is meeting the needs of a dynamic market and continuing its international expansion efforts Hims & Hers Health, Inc. (NYSE:HIMS), the leading health and wellness platform, today announced the availability of generic semaglutide through its platform in Canada. This is Hims & Hers' first international generic GLP-1 offering, demonstrating the company's ability to meet the unique needs of each global market it serves while continuing its international expansion efforts. Personalized treatment plans are available starting at $149 CAD/month, making effective, affordable GLP-1s accessible to Canadians for whom cost has long bee
- PRHims & Hers Brings First-Time Access to Generic Semaglutide to CanadaPersonalised treatment plans pair medication with unlimited Care Team support, nutrition and lifestyle guidance, and Canadian medical expertise, starting at $149/month Hims & Hers Health, Inc. (NYSE:HIMS), the leading health and wellness platform, today announced the availability of generic semaglutide through its platform for eligible customers in Canada. This makes affordable GLP-1 treatment accessible to Canadians for whom cost has long been a barrier to treatment. For eligible customers, personalised treatment plans are available starting at $149/month CAD. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260520762631/en/Per
- PRPeptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness MarketsNEW YORK, May 21, 2026 (GLOBE NEWSWIRE) -- Market News Updates News Commentary - The market for peptide-based health and performance products has been growing fast as more consumers focus on fitness, recovery, longevity, weight management, and overall wellness. Peptides are being widely explored for areas tied to muscle recovery, metabolic health, anti-aging research, and performance optimization. What used to be a niche biotech category is now attracting attention from wellness brands, pharmaceutical companies, and investors looking for exposure to one of the faster-growing areas of healthcare innovation. Those seeking high-growth opportunities in wellness and biotech should watch these c
- INSIDERChief Financial Officer Okupe Oluyemi exercised 7,950 shares at a strike of $5.01 and sold $187,916 worth of shares (7,950 units at $23.64) as part of a pre-agreed trading plan (SEC Form 4)4 - Hims & Hers Health, Inc. (0001773751) (Issuer)
- SECHims & Hers Health Inc. filed SEC Form 8-K: Other Events8-K - Hims & Hers Health, Inc. (0001773751) (Filer)
- PRHims & Hers Health, Inc. Prices Upsized $350 Million Convertible Senior Notes Offering to Support International Expansion and Accelerate AI-Driven Platform InvestmentProceeds intended to be used to preserve financial flexibility as Hims & Hers executes on its international expansion strategy, including the proposed acquisition of Eucalyptus, invests in technology and operational infrastructure to drive anticipated cost efficiencies, and enhances the consumer experience with AI and its closed-loop data ecosystem. Hims & Hers Health, Inc. (("Hims &, Hers" or the "Company", NYSE:HIMS) today announced the pricing of its offering of $350 million aggregate principal amount of 0.00% convertible senior notes due 2032 (the "notes") in a private offering to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securiti
- PRHims & Hers Health, Inc. Announces Proposed Convertible Senior Notes Offering to Support International Expansion and Accelerate AI-Driven Platform InvestmentProceeds intended to be used to preserve financial flexibility as Hims & Hers executes on its international expansion strategy, including the proposed acquisition of Eucalyptus, invests in technology and operational infrastructure to drive anticipated cost efficiencies, and enhances the consumer experience with AI and its closed-loop data ecosystem. Hims & Hers Health, Inc. (("Hims &, Hers" or the "Company", NYSE:HIMS) today announced its intention to offer, subject to market and other conditions, $300 million aggregate principal amount of convertible senior notes due 2032 (the "notes") in a private offering to persons reasonably believed to be qualified institutional buyers pursuant to R
- SECSEC Form SCHEDULE 13G filed by Hims & Hers Health Inc.SCHEDULE 13G - Hims & Hers Health, Inc. (0001773751) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Hims & Hers Health Inc.SCHEDULE 13G/A - Hims & Hers Health, Inc. (0001773751) (Subject)
- PRThe $59B Quiet Shift Reshaping How Patients Access CareIssued on behalf of VentriPoint Diagnostics Ltd.Equity-Insider.com News CommentaryVANCOUVER, BC, May 12, 2026 /CNW/ -- Point-of-care diagnostics just crossed $58.76 billion globally in 2026, growing at nearly 10% annually as testing that used to require a hospital lab now fits on a clinic counter or a patient's nightstand[1]. That capital rotation is real: digital health startups pulled in $4 billion in Q1 alone, the strongest first quarter since the pandemic peak, with average deal sizes at levels not seen since late 2021[2]. Investors are not chasing drug discovery this cycle; they are backing companies that can deliver clinical-grade results through faster, lighter, cheaper channels, and
- ANALYSTNeedham reiterated coverage on Hims & Hers Health with a new price targetNeedham reiterated coverage of Hims & Hers Health with a rating of Buy and set a new price target of $35.00 from $30.00 previously
- PRPeptide Wellness Market Could Near $300 Billion as Consumer Demand AcceleratesNEW YORK, May 12, 2026 (GLOBE NEWSWIRE) -- Market News Updates News Commentary -- Investor interest in the next-generation wellness market is picking up fast as peptide-based health and performance products become more mainstream. More consumers are looking for wellness solutions that go beyond traditional supplements — products designed to support energy, recovery, metabolism, healthy aging, fitness, and overall well-being. As people become more focused on taking control of their health earlier in life, demand for science-backed peptide products continues to grow, creating major opportunities for companies developing high-quality formulations and modern wellness platforms. Investors looki
HIMS FAQ
7 questionsWhat does Hims & Hers Health Inc. do?
Hims & Hers Health, Inc. operates a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals. The company offers a range of health and wellness products and services available for purchase on its websites directly by customers. It provides prescription medication on a recurring basis and ongoing care from healthcare providers; and over-the-counter drug and device products, as well as cosmetics and supplement products, primarily focusing on wellness, sexual health, skincare, and hair care. The company's curated non-prescription products include vitamin...Where does HIMS stock trade?
Hims & Hers Health Inc. (HIMS) is listed on NYSE.What sector and industry is HIMS in?
Hims & Hers Health Inc. operates in the Health Care sector, Medical/Nursing Services industry.When did Hims & Hers Health Inc. go public?
Hims & Hers Health Inc. (HIMS) completed its IPO in 2019.What are analysts saying about HIMS?
Hims & Hers Health Inc. has had 8 recent analyst actions on file. The most recent action was from Needham: Buy with a $3500.00 price target on 2026-05-12. Recent price targets range from $2300.00 to $4800.00.What companies are similar to HIMS?
Notable peers in the same industry include BTSG (BrightSpring Health Services Inc.), CHE (Chemed Corp), AMED (Amedisys Inc), LHCG (LHC Group), OPCH (Option Care Health Inc.). Compare HIMS side-by-side with any of them on Quantisnow.How can I track HIMS on Quantisnow?
Quantisnow aggregates Hims & Hers Health Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow HIMS to receive live email and push alerts on every new disclosure.